» Articles » PMID: 36311306

Interprofessional Collaboration Between a Clinical Pharmacist and Specialty Physicians to Treat Hepatitis C in an Interdisciplinary Medical Practice Setting

Overview
Journal J Pharm Technol
Publisher Sage Publications
Date 2022 Oct 31
PMID 36311306
Authors
Affiliations
Soon will be listed here.
Abstract

Describes the activities of a clinical pharmacist in a gastroenterology (GI) clinic providing services to hepatitis C virus (HCV) patients, with a focus on practice management activities and tools. Located inside a GI specialty clinic in Fort Worth, Texas, the pharmacist provides comprehensive medication management under a collaborative practice agreement (CPA). Once referred by the GI physician, the pharmacist has face-to-face patient visits, develops the care plan, orders medications, and follows patients through sustained virologic response and the development of a hepatocellular carcinoma surveillance plan. The role of pharmacists in the management of HCV is important to understand. This article details a pharmacist-led clinic in an open GI medical practice. A retrospective chart review study was conducted to assess outcomes related to the integration of the clinical pharmacist. Completed by the study team, this study included manual chart reviews of patients with the ambulatory care pharmacist-driven HCV practice to pull data and information that were then tabulated using Qualtrics. A total of 95 charts were surveyed, 78 records were created, and 49 patients were started on direct-acting antiviral (DAA) treatment by the pharmacist. Patients required multiple pharmacist communication actions. The minimum duration of the pharmacist service was 6 months and could extend more than 9 months depending on the time it took to get the patient started on medication. Pharmacist integration into the practice resulted in improved intake for the GI clinic, improved interprofessional interaction, and increased utilization of newer treatment modalities for HCV which feature cure rates up to 99% with limited side effects. Clinical pharmacists are well positioned to help navigate patients through the complexities of the medication use system, medication access, drug interactions and adverse effects, promote medication adherence, and allow patients to start and complete therapy.

References
1.
Gooch K, Culleton B, Manns B, Zhang J, Alfonso H, Tonelli M . NSAID use and progression of chronic kidney disease. Am J Med. 2007; 120(3):280.e1-7. DOI: 10.1016/j.amjmed.2006.02.015. View

2.
Gunn J, Higgs P . Pharmacies dispensing opioid substitution therapy also play a role in hepatitis C virus elimination. J Am Pharm Assoc (2003). 2018; 58(3):245. DOI: 10.1016/j.japh.2018.01.008. View

3.
Ghany M, Morgan T . Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2019; 71(2):686-721. PMC: 9710295. DOI: 10.1002/hep.31060. View

4.
Geiger R, Steinert J, McElwee G, Carver J, Montanez R, Niewoehner J . A Regional Analysis of Hepatitis C Virus Collaborative Care With Pharmacists in Indian Health Service Facilities. J Prim Care Community Health. 2018; 9:2150132718807520. PMC: 6201170. DOI: 10.1177/2150132718807520. View

5.
Carrozzo M, Scally K . Oral manifestations of hepatitis C virus infection. World J Gastroenterol. 2014; 20(24):7534-43. PMC: 4069285. DOI: 10.3748/wjg.v20.i24.7534. View